Xilio Therapeutics, Inc. (XLO) Stock Price & Analysis
Xilio Therapeutics, Inc. (XLO) — MoonshotScore 22/100 (Weak band), calculated Oct 5, 2026. Price $9.01 (+1.12%), as of the Oct 2, 2026 trading session; market cap $59.2M.
Educational signal · not a buy or sell recommendation · How to read this
Xilio Therapeutics, Inc. · XLO · NASDAQ
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing tumor-selective immunotherapies for cancer patients.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Xilio Therapeutics (XLO)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Durable growth, but weak quality and a strained balance sheet. Business Quality: Thin; Financial Safety: Strained; Valuation: Full; Growth Durability: Growing; Momentum: Rising.
- quarterly revenue $19M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 5 of 8
- Altman Z -2.70 · Piotroski F 3
Helping: durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 22 | Weak | |
| 22 | Weak | |
| 22 | Weak | |
| 22 | Weak | |
| 22 | Weak | |
| 22 | Weak |
The score was 22 in the stored Oct 4, 2026 snapshot and remains 22 in the current publication computed Oct 5, 2026 (0). This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $9.01 | |
| Change on the day | +1.12% | |
| 52-week range | $6.47 – $12.59 | |
| Market capitalisation | $59.2M | |
| Shares traded on the day | 7.2K |
Price & events
Council Score · weighted blend of 2 available disciplines
Council score for Xilio Therapeutics (XLO): Bearish Lean
33/100 · DSome lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
2 lenses, 2 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 5, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 9, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the XLO film — every key number, told as a short cinematic story
~2 min · open the film
What is Xilio Therapeutics (XLO), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Xilio Therapeutics, Inc. (XLO) is listed on NASDAQ. It employs 76 people and is led by Rene Russo. In Q2 FY2026 it reported revenue of $19M and net income of -$6M. The market values it at $59.2M.
What do the latest results show for Xilio Therapeutics (XLO)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $19M. Against analyst estimates the company has EPS beat 5 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $19M | -$6M | -$0.33 (diluted) |
| Q1 FY2026 | $13M | -$10M | -$0.06 (diluted) |
| Q4 FY2025 | $14M | $10M | $0.12 (diluted) |
| Q3 FY2025 | $19M | -$16M | -$1.58 (diluted) |
What are the financial strengths and risks for Xilio Therapeutics (XLO)?
Short answer
The MoonshotScore pillars rate durable growth as strengths. The distress and quality screens read Altman Z -2.70 · Piotroski F 3. Trailing ratios: ROE -50.8% · ROA -14.2% · current ratio 4.25 · earnings yield -12.4%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -2.70 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-50.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
How is Xilio Therapeutics scored?
Short answer · as of
A same-model peer rank is unavailable in the current peer set. The MoonshotScore combines business quality, financial safety, valuation, growth durability and momentum; open “Why this rating?” for the method and drivers.
| Company | Price | Market value | Score |
|---|---|---|---|
| $9.75 Date unavailable | $88.2M | — Model unavailable | |
| $17.08 Date unavailable | $90.6M | — Model unavailable | |
| $9.96 Date unavailable | $119M | — Model unavailable | |
| $4.49 Date unavailable | $184M | — Model unavailable | |
| $5.71 Date unavailable | $206M | — Model unavailable | |
| $2.71 Date unavailable | $218M | — Model unavailable | |
| $2.79 Date unavailable | $222M | — Model unavailable | |
| $8.23 Date unavailable | $245M | — Model unavailable | |
| $7.19 Date unavailable | $564M | — Model unavailable | |
| $9.99 Date unavailable | $591M | — Model unavailable | |
| $10.94 Date unavailable | $626M | — Model unavailable | |
| $4.59 Date unavailable | $669M | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Available records within the last 180 days, newest dated Jun 11, 2026 (coverage not recorded)
- Transactions
- 8
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 0
- Other transactions
- 8
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about Xilio Therapeutics (XLO)?
What Investors Ask About Xilio Therapeutics (XLO)
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for XLO?
XLO carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is XLO a good stock to buy?
Stock Expert AI does not rate XLO buy, sell or hold. Xilio Therapeutics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the XLO stock price today?
The last price recorded on this page for Xilio Therapeutics, Inc. (XLO) is $9.01, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for XLO?
Xilio Therapeutics, Inc. (XLO) holds a MoonshotScore in the low range. Not financial advice.
How frequently does XLO data refresh on this page?
XLO's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven XLO's recent stock price performance?
Xilio Therapeutics, Inc. (XLO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary tumor-selective masking technology for cytokine programs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider XLO overvalued or undervalued right now?
Xilio Therapeutics, Inc. (XLO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of XLO?
Fractional-share availability for Xilio Therapeutics, Inc. (XLO) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
How can I track XLO's earnings and financial reports?
Xilio Therapeutics, Inc. (XLO) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for XLO earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (17 figures)
The 17 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 9 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $9.01 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T06:34:22.479Z. | |
px.change | Change on the day | +1.12% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $59.2M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-05T06:34:21.348Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.10 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $19M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.volume | Shares traded on the day | 7.2K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_income | Net income, Q2 FY2026 | -$6M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.insiders | Insider transactions via FMP | 8 transactions · 0 purchases, 0 sales, 8 other transactions · 8 identified insiders · available records within the last 180 days, newest dated Jun 11, 2026 (coverage not recorded) | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 5 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-16 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -2.70 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
px.range52 | 52-week range | $6.47 – $12.59 | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
id.employees | Employees | 76 | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
id.ceo | Chief executive | Rene Russo | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -50.8% · ROA -14.2% · current ratio 4.25 · earnings yield -12.4% | — | UNRECORDED | Stored key metrics — Date unknown |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 22 of 100 · Weak · pillars 35 / 35 / 47 / 70 / 60 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 22 (stored snapshot Oct 4, 2026) → 22 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.